The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control
In 2008, the US Food and Drug Administration (FDA) issued guidance to the pharmaceutical industry to...
Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, sp...
Introduction: Individuals with type 2 diabetes mellitus (T2DM) have increased cardiovascular risk wi...
The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose f...
This review examines recent randomized controlled cardiovascular (CV) outcome trials of glucose-lowe...
In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical indust...
AbstractSince the time questions arose on cardiovascular safety of Rosiglitazone, FDA has suggested ...
The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of ...
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1...
<div><p></p><p>This manuscript is a result of the efforts of the American Statistical Association Bi...
In people with Type 2 diabetes, cardiovascular disease is a leading cause of morbidity and mortality...
Funding Information: MM participated in advisory board meetings and received speaker’s fees from the...
Glucose lowering drugs have been available for clinical use for over the past 60 years or so with th...
L ingering questions related to cardio-vascular (CV) safety of type 2 di-abetes treatments resulted ...
The evidence for using statins in diabetic patients with normal cholesterol levels to prevent myocar...
In 2008, the US Food and Drug Administration (FDA) issued guidance to the pharmaceutical industry to...
Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, sp...
Introduction: Individuals with type 2 diabetes mellitus (T2DM) have increased cardiovascular risk wi...
The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose f...
This review examines recent randomized controlled cardiovascular (CV) outcome trials of glucose-lowe...
In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical indust...
AbstractSince the time questions arose on cardiovascular safety of Rosiglitazone, FDA has suggested ...
The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of ...
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1...
<div><p></p><p>This manuscript is a result of the efforts of the American Statistical Association Bi...
In people with Type 2 diabetes, cardiovascular disease is a leading cause of morbidity and mortality...
Funding Information: MM participated in advisory board meetings and received speaker’s fees from the...
Glucose lowering drugs have been available for clinical use for over the past 60 years or so with th...
L ingering questions related to cardio-vascular (CV) safety of type 2 di-abetes treatments resulted ...
The evidence for using statins in diabetic patients with normal cholesterol levels to prevent myocar...
In 2008, the US Food and Drug Administration (FDA) issued guidance to the pharmaceutical industry to...
Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, sp...
Introduction: Individuals with type 2 diabetes mellitus (T2DM) have increased cardiovascular risk wi...
DOI
Add to ORKG